During the past decade, Tokyo Women's Medical University Hospital conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 21 clinical trials were completed, i.e. on average, 48.8% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 15 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Women's Medical University Hospital" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Abbott Medical Devices" with 4 trials sponsored, "Biogen" with 4 trials sponsored, "Celgene" with 4 trials sponsored and "Tokyo Women's Medical University" with 4 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Women's Medical University Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 3 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Baxter Healthcare Corporation" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator and "Chugai" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Women's Medical University Hospital" are "Coronary Artery Disease" (5 trials), "Heart Failure" (3 trials), "Colorectal Cancer" (2 trials), "Diabetic Macular Edema" (2 trials) and "Ischemic Heart Disease" (2 trials). Many other conditions were trialed in "Tokyo Women's Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Women's Medical University Hospital" are "Drug" (46 trials), "Device" (14 trials), "Biological" (8 trials), "Procedure" (7 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Sham Procedure" (6 trials), "Faricimab" (5 trials), "Aflibercept" (3 trials) and "Nusinersen" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Women's Medical University Hospital" are 70 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Tokyo Women's Medical University Hospital". undefined are not yet recruiting, 11 are recruiting, 11 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 40 completed trials in Tokyo Women's Medical University Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Women's Medical University Hospital, 4 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 9 trials that are defined as “Not Applicable".

Tokyo Women's Medical University Hospital has several departments that took part in Clinical trials: "Institute of Rheumatology, Tokyo Women's Medical University" - 2 trials, "Tokyo Women's Medical University Hospital; Neurology" - 2 trials, "Institute of Rheumatology Tokyo Women's Medical University" - 2 trials